Clinical Trial Update: Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial

View source ↗

Summary

A clinical trial evaluating sorafenib for relapsed FLT3-ITD acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Sorafenib (Nexavar) (Sorafenib)

Snippet

Sponsor: Robert Zeiser | Conditions: Acute Myeloid Leukemia | Status: COMPLETED